Archived research. Equity forecasting is part of the Runchey Research archive (methodology era 1) and is no longer actively updated. Everything remains published at its original URL. Browse the archive
Will ATAI disclose an unplanned DSMB safety communication for BPL-003 Phase 3 trials by 2026-12-31?
Current Prediction
Why This Question Matters
Any unplanned DSMB safety communication during the 2026 Phase 3 ramp would be a critical tail-risk signal for Black Swan Beacon's 'Safety Signal at Phase 3 Scale' compound scenario (10-15% probability, EXISTENTIAL severity). Serotonergic psychedelics carry theoretical 5-HT2B-linked cardiovascular risk that Phase 2b (n=196) is too small to detect. A YES resolution would propagate through REGULATORY_EXPOSURE and TAIL_RISK_SEVERITY; a NO resolution confirms safety profile scales. Low base rate but asymmetric impact.
Prediction Distribution
Individual Predictions(9 runs)
Three-factor decomposition: (1) P(Phase 3 enrollment starts by Q3 2026) ~65%, (2) P(first DSMB review occurs within 3-6 months of FPD i.e. before 2026-12-31) ~40%, (3) P(unplanned communication at that review) ~8% base rate. Joint conditional probability of ATAI-specific unplanned DSMB event by 2026-12-31: 0.65 x 0.40 x 0.08 = 0.021. Add Category Backlash path (~7-12% probability of competitor-driven FDA class communication): approximately 5-8% additional probability. Net approximately 0.08 — dominated by category effect more than direct safety signal.
The Phase 2b safety profile was favorable (n=196, no serious drug-related AEs, patients discharge-ready in 2 hours). Breakthrough Therapy status enables FDA to intervene via protocol amendments BEFORE DSMB escalation — this lowers formal DSMB action probability meaningfully. Direct safety event probability 3-5%; category backlash probability 5-8%; some correlation but approximate union 0.10. Tail scenario includes 5-HT2B cardiovascular signal — theoretical but low near-term probability.
Slightly elevated. The post-Lykos FDA scrutiny environment may lower the threshold for proactive DSMB communication — what would have been handled informally pre-2024 may now be formalized. Add 3-4% to base estimate for this elevated regulatory posture. Also consider that ATAI's dosing protocol (monitored clinical settings, 2-hour observation) is designed to surface AEs quickly, which increases the probability that any observed signal escalates to DSMB attention. Net 0.12.
Base rate for unplanned DSMB communication in Phase 3 psychiatric drug trial within first 6-8 months of enrollment: 3-6%. Category backlash path adds 4-6%. If Phase 3 FPD slips, the window compresses (mechanically reduces probability). Weighted net 0.09. Strict definition of 'unplanned' filters out routine DSMB outputs.
Conservative. Phase 2b clean safety + Breakthrough designation + monitored clinical setting + short 2026 observation window all point to low probability. Most meaningful DSMB interactions will happen 2027+. The 'unplanned' strict definition is a significant filter — many DSMB reviews are scheduled and produce routine outputs that do not qualify. Net 0.07.
Balanced. Direct signal 4-5%, category effect 5-6%, weak correlation implies approximate union 0.09-0.11. Post-Lykos environment + serotonergic class theoretical risks + 700-1000 patient Phase 3 scale all support ~0.10. Phase 2b positive safety is the strongest counterweight but has limited power for rare events.
Base rate 3-6% for unplanned DSMB in psychiatric Phase 3 first 6-8 months. Category path 4-6%. Union 0.08.
Serotonergic psychedelic class + post-Lykos scrutiny + 700-1000 patient scale elevate above pure base rate. Still dominated by low base rate for any single-window event. 0.09.
Base rate anchor. Phase 2b safety clean + Breakthrough + 2026 window mostly pre-meaningful-data = low probability. 0.08.
Resolution Criteria
Resolves YES if by 2026-12-31 ATAI publicly discloses (via 8-K, press release, earnings call, or ClinicalTrials.gov update) any unplanned DSMB communication for BPL-003 Phase 3 trials — including but not limited to: enrollment pause, protocol amendment triggered by safety review, serious adverse event notification, activation of a stopping rule, or DSMB recommendation to FDA. Resolves NO if no such disclosure occurs by 2026-12-31. Planned/scheduled interim DSMB meetings without safety-driven recommendations do NOT trigger YES.
Resolution Source
ATAI 8-K filings, press releases, quarterly earnings calls, ClinicalTrials.gov updates, FDA safety communications
Source Trigger
DSMB interim safety communications — any unplanned DSMB disclosure
Full multi-lens equity analysis